SCHEMBL8209034

SCHEMBL8209034

Cc1cccc(-n2cc(CNC(=O)c3cccc(C(=O)NC(C)C)n3)cn2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.47
DDT P30046 1/20 0.45
KCNT1 Q5JUK3 2/20 0.42
MMP13 P45452 1/20 0.42
SMO Q99835 1/20 0.42
GCGR P47871 1/20 0.41
POLB P06746 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADORA1 P30542 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MIF P14174 1/20 0.39
TSHR P16473 1/20 0.39
KLKB1 P03952 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8210993 0.90 ADRB2 (0.46) ADRB2GCGRPOLBKDM4EADORA1
SCHEMBL8205629 0.90 CNR1 (0.43) ADRB2POLBLMNACYP1A2ALDH1A1
SCHEMBL12853254 0.90 HPGD (0.44) ADRB2POLBKDM4ELMNACYP2C9
SCHEMBL8211521 0.89 ADRB2 (0.57) ADRB2DDTSMOPOLBKDM4E
SCHEMBL8206269 0.89 ADRB2 (0.45) ADRB2DDTPOLBKDM4EALDH1A1
SCHEMBL17011995 0.88 ADRB2 (0.46) ADRB2DDTPOLBKDM4EALDH1A1
SCHEMBL8212612 0.88 ADRB2 (0.47) ADRB2DDTKCNT1MMP13SMO
SCHEMBL8207649 0.88 ADRB2 (0.45) ADRB2DDTKCNT1MMP13SMO
SCHEMBL12853294 0.87 KDM4E (0.44) ADRB2POLBKDM4ELMNAALDH1A1
SCHEMBL12853297 0.87 DDT (0.53) ADRB2DDTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132178-B1 JNK INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 EP disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
WO-2008082487-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179141-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK5, MAPK15 ADRB2 3238/4885DDT 4423/4885KCNT1 3530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.